PathMaker Neurosystems is a clinical-stage neuromodulation company founded to commercialize recent advances in the development of non-invasive devices that suppress neuronal hyperexcitability and activate neuronal protein degradation pathways.  We are focused on rapidly bringing to market revolutionary products for non-invasively treating ALS (amyotrophic lateral sclerosis) and other serious neurological disorders.  Based on extensive pre-clinical animal studies, elucidation of molecular mechanisms and human clinical studies, the Company is advancing an entirely novel treatment paradigm based on multi-site direct current stimulation (Multi-Site DCS). Our proprietary technology is able to non-invasively restore neural pathways damaged by ALS and other serious neurological disorders by normalizing pathway overactivity and reducing protein aggregation in motor neurons.

Connect with us on: